Genor Biopharma Holdings (STU:67N) Total Stockholders Equity : €151.04 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Genor Biopharma Holdings Total Stockholders Equity?

Genor Biopharma Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €151.04 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Genor Biopharma Holdings's Book Value per Share for the quarter that ended in Dec. 2024 was €0.29. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Genor Biopharma Holdings's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.00.

Genor Biopharma Holdings Total Stockholders Equity Historical Data

The historical data trend for Genor Biopharma Holdings's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings Total Stockholders Equity Chart

Genor Biopharma Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

406.53

346.01

244.06

152.68

151.04

Genor Biopharma Holdings Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial							244.06	201.54	152.68	136.00	151.04

Genor Biopharma Holdings (STU:67N) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Genor Biopharma Holdings's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(151.038	-	0)	/	516.815
	=	0.29

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Genor Biopharma Holdings's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.047	+	0.073)	/	151.038
	=	0.00

Genor Biopharma Holdings Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Genor Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (STU:67N) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

06998:Hong Kong

Address

690 Bibo Road, Room 501-02, Building 6, Pudong New District, Shanghai, CHN, 201203

Website

https://www.genorbio.com

Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.

Genor Biopharma Holdings Headlines

No Headlines